Next |
home / stock / phar / phar message board
Subject | By | Source | When |
---|---|---|---|
must see | lifegear | investorshub | 05/09/2023 2:15:22 AM |
just the news we needed | surfkast | investorshub | 05/08/2023 1:43:08 PM |
$PHAR bulls and bears | vladimirr | investorshub | 05/08/2023 11:45:38 AM |
short squeeze signal | jackluna | investorshub | 05/05/2023 5:18:25 PM |
Price now up | SilverFox97 | investorshub | 05/05/2023 4:19:17 PM |
$PHAR bears and bulls | mzasif | investorshub | 05/03/2023 2:05:54 AM |
should we be shorting? | SilverFox97 | investorshub | 04/30/2023 11:10:16 PM |
$PHAR Looks pretty positive | ggecko50 | investorshub | 04/30/2023 10:14:53 PM |
$PHAR Lets go go go go... Up up and away we go. | surfkast | investorshub | 04/26/2023 3:55:33 PM |
$PHAR Price gaining | neil1 | investorshub | 04/26/2023 11:11:36 AM |
got some short data | lifegear | investorshub | 04/26/2023 1:26:26 AM |
When is this gonna take off? | sidedraft | investorshub | 04/25/2023 12:07:06 PM |
and the shorts continue | sidedraft | investorshub | 04/22/2023 8:30:31 PM |
$PHAR MomentumIts gaining | stocksablaze | investorshub | 04/22/2023 3:04:58 PM |
MomentumIts gaining last up | surfkast | investorshub | 04/20/2023 7:23:57 AM |
short squeeze all day | surfkast | investorshub | 04/19/2023 5:55:25 PM |
$PHAR MomentumIts gaining | sidedraft | investorshub | 04/19/2023 5:08:33 AM |
where is the squeeze? | aquaspin | investorshub | 04/19/2023 12:16:14 AM |
short squeeze signal | sidedraft | investorshub | 04/17/2023 3:35:51 PM |
The now | playerguy | investorshub | 04/15/2023 12:08:54 PM |
News, Short Squeeze, Breakout and More Instantly...
Pharming Group N.V. Company Name:
PHAR Stock Symbol:
NASDAQ Market:
Apartment Investment and Management Company (AIV) is expected to report for Q1 2024 Shopify Inc. Class A Subordinate (SHOP) is expected to report $0.08 for Q1 2024 Beyond Meat Inc. (BYND) is expected to report $-0.68 for Q1 2024 Instructure Holdings Inc. (INST) is expected to report $...
Recognition given for achievement in commercializing Joenja® (leniolisib), a first-in-class medication brought to market 10 years after disea...
This multinational Phase III study is evaluating leniolisib tablets in children aged 4 to 11 years with APDS, a rare primary immunodeficiency Leid...